Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.